Alpha Tau Medical (NASDAQ:DRTS) Shares Down 2% - What's Next?

Key Points

• Alpha Tau Medical's shares experienced a 2% decline, trading down to about $4.31, with a notable drop in trading volume, down 56% from the average.
• According to research, Weiss Ratings issued a "sell" rating while HC Wainwright maintained a "buy" rating with a target price of $9.00, leading to an average rating of "Hold" for the stock.
• The company's quarterly earnings report revealed a loss of $0.13 per share, which was below analysts' expectations and contributed to projections of a -0.45 EPS for the current year.

Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) shares fell 2% during mid-day trading on Friday . The stock traded as low as $4.30 and last traded at $4.31. 27,766 shares were traded during trading, a decline of 56% from the average session volume of 62,805 shares. The stock had previously closed at $4.40.

Wall Street Analyst Weigh In

DRTS has been the subject of a number of research reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Alpha Tau Medical in a research note on Saturday, September 27th. HC Wainwright reissued a "buy" rating and set a $9.00 target price on shares of Alpha Tau Medical in a report on Wednesday, September 3rd. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $9.00.

Alpha Tau Medical Stock Performance

The company has a current ratio of 10.52, a quick ratio of 5.81 and a debt-to-equity ratio of 0.07. The stock's fifty day simple moving average is $3.57 and its 200 day simple moving average is $3.10. The company has a market cap of $365.57 million, a price-to-earnings ratio of -8.98 and a beta of 1.07.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.01). As a group, analysts anticipate that Alpha Tau Medical Ltd. will post -0.45 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Alpha Tau Medical stock. XTX Topco Ltd acquired a new position in shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 21,195 shares of the company's stock, valued at approximately $53,000. Hedge funds and other institutional investors own 2.65% of the company's stock.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.